Landmark Research Studies
ongoing

COMPASS was a randomized controlled trial that discovered that the use of rivaroxaban, a new antithrombotic treatment, reduces heart attacks, strokes, amputations and death in patients with coronary artery disease (CAD) or peripheral arterial disease (PAD).

Findings of the COMPASS trial resulted in regulatory approval of rivaroxaban for CAD and PAD by regulators around the world.

Primary efficacy outcome:

Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death, over approximately five years.

Primary safety outcome:

Time from randomization to the first occurrence of major bleeding (modified International Society on Thrombosis and Haemostasis), over approximately five years.

The randomized trial is complete; the open label extension of COMPASS is ongoing.

Download Presentation PDF
Study Type

Interventional - Drug

Study Design

RCT double-blind

NO. of Countries

33

NO. of Sites

602

NO. of Participants

27395

Study Period

2013-2017

Sponsor

BAYER

JOHN EIKELBOOM DISCUSSES COMPASS

Bayer

Janssen Research & Development

Back To Top